Moderna (NASDAQ:MRNA) Sets New 12-Month Low – Here’s Why

Shares of Moderna, Inc. (NASDAQ:MRNA) hit a new 52-week low during trading on Thursday . The stock traded as low as $22.50 and last traded at $22.3730, with a volume of 14843181 shares changing hands. The stock had previously closed at $24.18.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MRNA. UBS Group decreased their target price on shares of Moderna from $70.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, October 23rd. Citigroup decreased their price objective on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Thursday, October 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. Bank of America cut their price target on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a research report on Monday, November 10th. Finally, JPMorgan Chase & Co. lowered their price objective on Moderna from $26.00 to $25.00 and set an “underweight” rating for the company in a research report on Thursday, October 23rd. One investment analyst has rated the stock with a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the company. According to MarketBeat, Moderna presently has an average rating of “Reduce” and a consensus price target of $28.50.

Moderna Stock Down 7.5%

The firm’s 50 day simple moving average is $25.93 and its two-hundred day simple moving average is $27.01. The stock has a market capitalization of $8.74 billion, a P/E ratio of -2.77 and a beta of 2.02.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $893.29 million. During the same period last year, the business posted $0.03 EPS. The firm’s revenue for the quarter was down 45.4% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Institutional Investors Weigh In On Moderna

Several hedge funds and other institutional investors have recently modified their holdings of MRNA. S Bank Fund Management Ltd bought a new position in shares of Moderna in the 1st quarter worth $25,000. Rothschild Investment LLC raised its holdings in Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after buying an additional 446 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Moderna by 348.8% in the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after buying an additional 743 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of Moderna during the second quarter valued at about $26,000. Finally, SVB Wealth LLC bought a new stake in shares of Moderna during the first quarter worth about $28,000. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.